{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:50:39Z","timestamp":1788346239843,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11882-020-00910-y","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T10:03:02Z","timestamp":1587549782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis"],"prefix":"10.1007","volume":"20","author":[{"given":"W. Colby","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Senior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"910_CR1","first-page":"S3","volume":"6","author":"RR Orlandi","year":"2016","unstructured":"Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: Rhinosinusitis executive summary. Int Forum Allergy Rhinol. 2016;6:S3\u201321.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"910_CR2","first-page":"1035","volume":"15","author":"GA Scangas","year":"2017","unstructured":"\u2022 Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R, Bachert C, et al. The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps. Lancet. 2017;15(1):1035\u201344 Markov analysis of cost of surgery compared with medical therapy alone.","journal-title":"Lancet."},{"key":"910_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","volume":"123","author":"CD Codispoti","year":"2019","unstructured":"\u2022 Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol American College of Allergy, Asthma and Immunology. 2019;123:232\u20139 Review summarizing what a cost-efficacy study for biologics in CRS should include.","journal-title":"Ann Allergy Asthma Immunol American College of Allergy, Asthma and Immunology"},{"issue":"S29","key":"910_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinol J. 2020;58(S29):1\u2013464.","journal-title":"Rhinol J"},{"issue":"4","key":"910_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11882-017-0690-5","volume":"17","author":"L Rudmik","year":"2017","unstructured":"Rudmik L. Economics of chronic rhinosinusitis. Curr Allergy Asthma Rep. 2017;17(4):20.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"910_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1945892418787132","volume":"32","author":"KA Smith","year":"2018","unstructured":"Smith KA, Pulsipher A, Gabrielsen DA, Alt JA. Biologics in chronic rhinosinusitis: an update and thoughts for future directions. Am J Rhinol Allergy. 2018;32(5):412\u201323.","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"910_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/lary.24916","volume":"125","author":"L Rudmik","year":"2015","unstructured":"Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL. Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis. Laryngoscope. 2015;125(1):25\u201332.","journal-title":"Laryngoscope."},{"issue":"1","key":"910_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/lary.26169","volume":"127","author":"GA Scangas","year":"2017","unstructured":"Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis. Laryngoscope. 2017;127(1):29\u201337.","journal-title":"Laryngoscope."},{"key":"910_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/BTT.S180846","volume":"12","author":"C Incorvaia","year":"2018","unstructured":"Incorvaia C, Mauro M, Makri E, Leo G, Ridolo E. Two decades with omalizumab: what we still have to learn. Biol Targets Ther. 2018;12:135\u201342.","journal-title":"Biol Targets Ther"},{"issue":"8","key":"910_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.waojou.2019.100050","volume":"12","author":"L Ren","year":"2019","unstructured":"\u2022 Ren L, Zhang N, Zhang L, Bachert C. Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art. World Allergy Organ J. 2019;12(8):1\u20136 Review of the current state of biologics.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"910_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1945892418814768","volume":"33","author":"AG Kartush","year":"2019","unstructured":"Kartush AG, Schumacher JK, Shah R, Patadia MO. Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2019;33(2):203\u201311.","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"910_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"910_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12890-019-0952-1","volume":"19","author":"T Numata","year":"2019","unstructured":"Numata T, Nakayama K, Utsumi H, Kobayashi K, Yanagisawa H, Hashimoto M, et al. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulm Med. 2019;19(1):176.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"910_CR14","doi-asserted-by":"publisher","first-page":"989-995.e8","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"Philippe Gevaert","year":"2011","unstructured":"Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-95.e1-8.","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"910_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024\u201331.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"910_CR16","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","volume":"5","author":"C Bachert","year":"2017","unstructured":"Bachert C, Gevaert P, Hellings P. Biotherapeutics in chronic rhinosinusitis with and without nasal polyps. J Allergy Clin Immunol Pract. 2017;5(6):1512\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"910_CR17","unstructured":"FDA announcement accessed 12\/30\/2019 [Internet]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-chronic-rhinosinusitis-nasal-polyps"},{"issue":"10209","key":"910_CR18","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"\u2022\u2022 Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350 Landmark study demonstrating efficacy of dupilumab.","journal-title":"Lancet."},{"issue":"10209","key":"910_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(19)32133-6","volume":"394","author":"WW Stevens","year":"2019","unstructured":"Stevens WW. A new treatment for chronic rhinosinusitis with nasal polyps. Lancet. 2019;394(10209):1595\u20137.","journal-title":"Lancet."},{"key":"910_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"910_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Eline Podevin C, Jachiet M, Bouaziz J-D, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"26","key":"910_CR22","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"910_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","volume":"77","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845\u201354.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"910_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","volume":"134","author":"A Long","year":"2014","unstructured":"Long A, Rahmaoui A, Rothman KJ, Guinan E, Eisner M, Bradley MS, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"910_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","volume":"139","author":"C Iribarren","year":"2017","unstructured":"Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol. 2017;139(5):1489\u201395.","journal-title":"J Allergy Clin Immunol"},{"key":"910_CR26","unstructured":"Tice JA, Walsh JM, Synnott P, Kumar V, Adair E, Rind D, et al. Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation. Inst Clin Econ Rev. 2018;1\u2013132."},{"issue":"2","key":"910_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","volume":"8","author":"SD Grosse","year":"2008","unstructured":"Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoeconomics Outcomes Res. 2008;8(2):165\u201378.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"key":"910_CR28","unstructured":"Dupixent pricing accessed 12\/31\/2019 [Internet]. Available from: https:\/\/www.dupixent.com\/dupixent-pricing"},{"issue":"4","key":"910_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","volume":"122","author":"WC Anderson","year":"2019","unstructured":"Anderson WC, Szefler SJ. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol. 2019;122(4):367\u201372.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"910_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","volume":"118","author":"MD Whittington","year":"2017","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"910_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","volume":"36","author":"RB McQueen","year":"2018","unstructured":"McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36(8):957\u201371.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"910_CR32","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/02770903.2018.1500584","volume":"56","author":"J Lam","year":"2019","unstructured":"Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019;56(8):872\u201381.","journal-title":"J Asthma"},{"issue":"10","key":"910_CR33","first-page":"987","volume":"24","author":"P Vadagam","year":"2018","unstructured":"Vadagam P, Kamal KM, Covvey JR, Giannetti V, Mukherjee K. Cost-effectiveness and budget impact of lumacaftor\/ivacaftor in the treatment of cystic fibrosis. J Manag care Spec Pharm. 2018;24(10):987\u201397.","journal-title":"J Manag care Spec Pharm"},{"issue":"12","key":"910_CR34","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ppul.24178","volume":"53","author":"SD Grosse","year":"2018","unstructured":"Grosse SD, Do TQN, Vu M, Feng LB, Berry JG, Sawicki GS. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018;53(12):1611\u20138.","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"910_CR35","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1164\/rccm.201810-1865ST","volume":"198","author":"MR Patel","year":"2018","unstructured":"Patel MR, Gerald JK, Gerald LB, Press VG, Barnes TBA, Blake K, et al. Improving the affordability of prescription medications for people with chronic respiratory disease an official American thoracic society policy statement. Am J Respir Crit Care Med. 2018;198(11):1367\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"910_CR36","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJMp1908688","volume":"381","author":"SB Dusetzina","year":"2019","unstructured":"Dusetzina SB, Keating NL, Huskamp HA. Proposals to redesign Medicare part D \u2014 easing the burden of rising drug prices. N Engl J Med. 2019;381(15):1401\u20134.","journal-title":"N Engl J Med"},{"issue":"8","key":"910_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jama.2019.1081","volume":"321","author":"H Bauchner","year":"2019","unstructured":"Bauchner H. Rationing of health care in the United States: an inevitable consequence of increasing health care costs. JAMA - J Am Med Assoc. 2019;321(8):751\u20132.","journal-title":"JAMA - J Am Med Assoc"},{"issue":"1","key":"910_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41385-019-0215-8","volume":"13","author":"Noriko Ogasawara","year":"2019","unstructured":"Ogasawara N, Poposki JA, Klingler AI, Tan BK, Hulse KE, Stevens WW, et al. Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps. Mucosal Immunol. 2020;13:86\u201395.","journal-title":"Mucosal Immunology"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-020-00910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-020-00910-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-020-00910-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:14:12Z","timestamp":1619050452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-020-00910-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["910"],"URL":"https:\/\/doi.org\/10.1007\/s11882-020-00910-y","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"22 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"16"}}